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REGULAR ARTICLE
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Key Points
• Soluble GPVI is ele-
vated in patients with
thermal injury with sep-
sis, and sGPVI levels
augment severity score
prediction of mortality.
• The GPVI ligand, fibrin,
induces GPVI shedding
without requirement for
platelet activation or
signaling
Soluble glycoprotein VI (sGPVI) is shed from the platelet surface and is a marker of platelet
activation in thrombotic conditions.Weassessed sGPVI levels togetherwithpatient and clinical
parameters in acute and chronic inﬂammatory conditions, including patients with thermal
injury and inﬂammatory bowel disease and patients admitted to the intensive care unit (ICU)
for elective cardiac surgery, trauma,acutebrain injury, orprolongedventilation. Plasma sGPVI
was measured by enzyme-linked immunosorbent assay and was elevated on day 14 after
thermal injury, andwas higher in patients who developed sepsis. sGPVI levelswere associated
withsepsis, andthevalue forpredictingsepsiswas increased incombinationwithplatelet count
and Abbreviated Burn Severity Index. sGPVI levels positively correlatedwith levels of D-dimer
(a ﬁbrin degradation product) in ICU patients and patients with thermal injury. sGPVI levels in
ICU patients at admission were signiﬁcantly associated with 28- and 90-day mortality
independentofplatelet count. sGPVI levels inpatientswith thermal injurywereassociatedwith
28-daymortality at days 1, 14, and 21when adjusting for platelet count. In both cohorts, sGPVI
associations with mortality were stronger than D-dimer levels. Mechanistically, release of
GPVI was triggered by exposure of platelets to polymerized ﬁbrin, but not by engagement of
G protein-coupled receptors by thrombin, adenosine 59-diphosphate, or thromboxane
mimetics. Enhanced ﬁbrin production in these patients may therefore contribute to the
observed elevated sGPVI levels. sGPVI is an important platelet-speciﬁc marker for platelet
activation that predicts sepsis progression and mortality in injured patients.
Introduction
Beyond its primary role in hemostasis, fibrin also contributes to thrombotic and inflammatory conditions.
Excessive fibrin formation occurs in acute and severe inflammation, including trauma,1-3 sepsis,4
disseminated intravascular coagulation (DIC),5 and deep vein thrombosis.6 Furthermore, fibrin deposition,
Submitted 31 July 2017; accepted 13 December 2017. DOI 10.1182/
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ablated fibrinolysis, and hypofibrinogenemia are associated with
multiple organ failure and mortality.7,8 Together with thrombocytopenia,
coagulation factor consumption, and acute coagulopathy,9,10 fibrin
formation and platelet activation are potentially linked in inflammatory
settings.
Glycoprotein (GP) VI is the major platelet signaling receptor for
collagen and fibrin,11,12 and GPVI-fibrin engagement may under-
pin fibrin-related disease pathology. GPVI is expressed only on
megakaryocytes and platelets13 in association with the Fc receptor
g-chain containing an immunoreceptor tyrosine-based activation
motif (ITAM).14 On resting platelets, GPVI is predominantly
monomeric, but clusters and dimerizes on activation,15-17 triggering
ITAM signaling involving Src family kinases.17,18 In hemostasis
and thrombosis, GPVI supports platelet adhesion and aggrega-
tion. GPVI is critical for the maintenance of vessel wall integrity
in inflammation19 by inhibiting neutrophil-induced vascular
damage.20,21
GPVI levels are stable on circulating platelets, but GPVI undergoes
rapid metalloproteolytic cleavage, and in some cases internalization,
on activation.22-25 GPVI shedding is induced by GPVI ligands
including collagen, collagen-related peptide (CRP), and venom
toxins,23,24,26,27 and by engagement of other platelet ITAM
receptors FcgRIIA and CLEC-2.28,29 Elevated fluid shear stress
and active factor X (FXa) also trigger GPVI shedding, quantified by
detection of the soluble ectodomain fragment (sGPVI) in plasma by
an enzyme-linked immunosorbent assay.30,31 Plasma sGPVI reflects
platelet activation in thrombotic conditions including microangiop-
athy,32 stroke,33 DIC,33 and Alzheimer’s disease34 and rheumatoid
arthritis.28,35 However, elevated plasma sGPVI levels in these
patient groups is surprising, as only a fraction of platelets would be
exposed to collagen, FXa, or elevated shear, and neither FcgRIIA or
CLEC-2 plays major roles in hemostasis/thrombosis. The recent
finding that fibrin activates GPVI provides a plausible explanation for
this increase.
Here, we report elevated sGPVI in inflammatory patient cohorts
including patients with injury, active inflammatory bowel disease
(IBD), and sepsis. sGPVI correlated with D-dimer levels in both
acute inflammatory patients admitted to an intensive care unit (ICU)
and patients with thermal injury. sGPVI was associated with sepsis
progression and mortality, and sGPVI levels enhanced APACHE
(Acute Physiology and Chronic Health Evaluation) II score pre-
diction of mortality. Furthermore, we show that fibrin induces GPVI
shedding in vitro, possibly explaining sGPVI elevation in patients
with acute injury.
Methods
Reagents
Refer to supplemental Material.
Blood collection
Healthy controls. Venous blood was collected from con-
senting, healthy volunteers into sodium citrate (4%) or 3.2%
trisodium citrate vacutainers (Becton Dickinson, Oxford, United
Kingdom). Ethical approval was granted by Birmingham University
Internal Ethical Review (ERN_11-0175).
ICU patients. Citrated blood was collected from 83 con-
senting patients admitted to tertiary ICU who underwent cardiac
surgery, trauma, invasive ventilation for more than 48 hours, or acute
brain injury at University Hospital of Lie`ge, Lie`ge, Belgium. (The
experimental protocol was approved by the ethics committee of the
University Hospital of Lie`ge [Centre Hospitalier Universitaire;
reference number B707201111981].). Sepsis diagnosis based
on previous sepsis definitions.36
Thermal injury patients. Ninety-nine patients with injury
afflicting up to 95% total body surface area (TBSA) were recruited
to the Scientific Investigation of the Biological Pathways Following
Thermal Injury Study (SIFTI: REC-12/EM/0432) at the Queen
Elizabeth Hospital, Birmingham, United Kingdom.37,38 Citrated
blood was collected at intervals after injury (day [D] 1, D3, D7,
D14, D21, and D28 and month 2, 3, 6, and 12 postinjury). Sepsis
diagnosis was made when more than 3 American Burn Association
criteria39 were met, plus positive bacterial culture and/or evidence
of antibiotic response.37 Platelet impedance counts were measured
using a Beckman-Coulter UniCel DxH-800 (HighWycombe, United
Kingdom) or a Sysmex XN-1000 Analyzer (Milton Keynes, United
Kingdom).
Patients with IBD. Citrated blood was collected from 42
consented patients diagnosed with inactive or active Crohn’s
disease and/or ulcerative colitis (UC; Ethics: REC:13/NE/0249).
Patient details can be found in the supplemental Material.
Plasma preparation
Platelet-free plasma was isolated from blood by serial centrifu-
gation: 2000g for 20 minutes and then 13 000g for 20 minutes
at 4°C for samples from patients with thermal injury and two
15-minute 2500g centrifugations at 37°C for samples from other
patient groups and healthy controls (HCs).
Washed platelet preparation and experiments
Washed platelets were prepared as described40 and washed
twice with calcium-free Modified Tyrode’s buffer (134 mM NaCl,
0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM
HEPES, 5 mM glucose, and 1 mM MgCl2 at pH 7.3) by
centrifugation at 1000g for 10 minutes and resuspended to
500 3 109 platelets/L. Washed platelets were preincubated for
5 minutes with 1 mM CaCl2 and with/without inhibitors (2 mM
GI254023, 25.7 mM GM6001, 10 mM PRT060318, or 10 mM
dasatinib) before addition of 9 mM eptifibatide (aIIbb3 inhibitor).
Platelet suspensions were stirred at 1200 rpm/37°C for 1
minute before agonist addition. For fibrin treatment, fibrinogen
(100 mg/mL) was added 3 minutes before thrombin (1 U/mL)
stimulation. Next, 10 mM Gly-Pro-Arg-Pro peptide (polymeriza-
tion inhibitor) was added to fibrinogen to achieve monomeric
fibrin conditions. Samples were stirred for 1 hour. Levels of
intact and proteolyzed GPVI were assessed by western blot,
using 1 mg/mL rabbit anti-human GPVI cytoplasmic tail antibody,
detecting intact and cleaved GPVI.23 Densitometry measure-
ments were made using Li-cor Image Studio software.
sGPVI Enzyme-Linked Immunosorbent Assay
sGPVI levels were measured by sandwich enzyme-linked immuno-
sorbent assay,28,30 and concentrations extrapolated from standard
curves generated by serial dilution of GPVI ectodomain into 5%
vol/vol GPVI-depleted plasma.28
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D-dimer measurements
D-dimer levels were measured in plasma using the Innovance
D-dimer immunoturbidimetric assay (Siemens Healthcare,
Eschborn, Germany).
Statistical analysis
Results are reported as mean 6 standard deviation, unless stated.
D’Agostino-Pearson normality tests determined normality. Student
t-tests were performed for normally distributed data; otherwise,
Mann-Whitney U tests were performed. For multiple groups,
Kruskal-Wallis tests with Dunn’s posttests were performed.
Univariate and multivariate logistic regression was used to analyze
variable association with 28- and 90-day mortality. Spearman’s rank
correlation coefficients assessed associations between sGPVI
levels and clinical parameters. Longitudinal analysis of sGPVI levels
on sepsis, multiple-organ failure, and mortality was performed using
linear mixed-effects models (supplemental Material). Statistical
analyses were performed using GraphPad Prism (versions 5, 7),
SPSS (IBM), and R (version 3.0.3).
Results
We assessed the utility of sGPVI as a biomarker of disease
pathology and progression in patients with injury, sepsis, and
inflammation by measuring sGPVI in samples from ICU patients,
patients with thermal injury, and patients with IBD.
sGPVI levels correlate with clinical and platelet-
specific parameters in ICU patients
Plasma sGPVI levels were measured in 83 ICU patients with acute
brain injury (n5 12), trauma (n5 13), elective cardiac surgery (n5
53), or prolonged ventilation (n 5 5). At T1 (day of ICU admission),
sGPVI levels were not significantly elevated above age-matched
HCs or at 48 hours postadmission (Figure 1A), although wide
ranges of sGPVI levels were observed at both points (5th-95th
percentiles: T1, 11.1-43.5 ng/mL; 48 hours, 12.1-39.8 ng/mL).
sGPVI at 48 hours increased in 42/83 patients (51%; Figure 1A). In
the 15 ICU patients who developed sepsis, sGPVI levels were not
elevated above T1 samples, both on day of sepsis diagnosis (Tx)
and 7 days after (Tx17), suggesting no elevations with sepsis onset
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Figure 1. sGPVI is detectable in patients admitted to ICU and associated with patient mortality. (A) sGPVI levels were measured in plasma from patients admitted to
ICU in samples obtained at day 1 (T1) and 48 hours after admission (n 5 83) compared with HCs (n 5 24). Blue dots represent sGPVI levels in patients that increased after
48 hours. Median shown. (B) sGPVI levels measured in ICU patients who developed sepsis at T1, 48 hours after admission, Tx (day of sepsis diagnosis), and Tx17. (C)
D-dimer levels of ICU patients at day 1 (T1) and 48 hours after admission to ICU. Levels below 0.5 mg/L FEU were considered normal, levels from 0.5 to 4.0 mg/L FEU
moderately increased, and levels more than 5.0 mg/L FEU strongly increased.41 (D) Association of sGPVI levels and patient mortality. Kaplan-Meier curve based on sGPVI
levels at T1. Solid line represents low sGPVI levels below the median (sGPVI low; #22.3 ng/mL), and the dotted line represents high sGPVI levels above the median (sGPVI
high; .22.3 ng/mL).
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or treatment phases of ICU patients (Figure 1B). sGPVI levels at T1
did not associate with sepsis occurrence, using a simple logistic
regression model (P 5 .085).
We compared sGPVI levels in ICU T1 patient samples against
biological and clinical parameters (Table 1). As expected, positive
correlations were seen with C-reactive protein, white blood cell
count, and APACHEII and Sequential Organ Failure Assessment
(SOFA) scores. Interestingly, platelet-related parameters, including
platelet count and fibrin(ogen)-binding, as well as D-dimer and
fibrinogen levels, also correlated significantly with sGPVI. After
correction for platelet count, D-dimer levels and platelet fibrin(ogen)-
binding remained significantly correlative at T1. D-dimer levels did not
increase at 48 hours (Figure 1C). In some patients, D-dimer levels
were elevated above 5 mg/L fibrinogen equivalent units (FEU),
representing a strong increase.41
sGPVI levels in ICU patients are associated
with mortality
sGPVI association with ICU patient mortality at T1 was assessed by
simple logistic regression, using a sGPVI cutoff based on median
levels found in healthy donors to stratify this cohort into low/normal
(#22.3 ng/mL) and elevated (.22.3 ng/mL) sGPVI groups. The
elevated sGPVI group showed reduced survival probability
(Figure 1D). Significant associations between T1 sGPVI with 28-
and 90-day mortality were also observed (supplemental Table 4).
This significant association remained when using multiple logistic
regression alongside platelet count (P 5 .036 and P 5 .014).
SOFA and APACHE(II) scores formed significant associations with
mortality (supplemental Table 4); however, sGPVI levels no longer
predicted mortality in patients with sepsis from this ICU cohort after
correction for disease severity. Interestingly, D-dimer levels and
platelet count formed no significant associations with 28- and 90-
day mortality at T1 (P 5 .059 and .058 and P 5 .220 and .077,
respectively; supplemental Table 4).
sGPVI is raised in thermal injury patients with sepsis
Although the range of sGPVI levels in HCs is tightly maintained,
sGPVI in longitudinal samples from 99 patients with thermal injury
with burns afflicting up to 95% TBSA burn (mean, 24%; IQR, 8%-
38%) showed a broad distribution (Figure 2A). sGPVI levels
increased from D1 postinjury, with a significant peak observed at
around D14 before slowly returning to HC levels by month 2
postinjury (Figure 2A).
sGPVI levels weakly correlated with platelet count in this cohort
(Spearman’s rank coefficient r5 0.119; P5 .015). Consistent with
other reports of significant platelet count reductions at D3 followed
by rebound thrombocytosis at D14 postinjury,42 here platelet
counts within septic and nonseptic patients reached a nadir at D3,
followed by rebound thrombocytosis peaking at D14 for nonseptic
patients and D21 for septic patients (Figure 2B).
A 58% incidence of sepsis occurred in this cohort, with onset
between D4 and D8 (median, 5.5 days).37 Septic patients had
higher peak sGPVI levels compared with nonseptic patients and
HCs (Figure 2C). After normalization for platelet count, sGPVI was
significantly elevated in septic patients compared with nonseptic
patients at D3, D7, D14, and D28 (Figure 2D), coincident with
sepsis onset and progression.
D-dimer levels in patients with thermal injury with burns of 15%
TBSA or more (n 5 61) increased from D1 postthermal injury to a
peak at D14, gradually normalizing during M3 (Figure 2E), echoing
sGPVI levels (Figure 2A). Significant positive correlation with D-dimer
and sGPVI levels were observed when assessing samples from all
points (r 5 0.35; Table 2). Alongside this, significant positive
correlations were seen at D14, D28, and month 2, with D14 giving
the strongest correlation (r 5 0.46; Table 2, sGPVI). D-dimer and
sGPVI correlations also strengthened after correction for platelet
count (Table 2, normalized sGPVI).
sGPVI levels in patients with thermal injury are
associated with sepsis and mortality
sGPVI associations with sepsis, multiple-organ failure, and mortality
were assessed in patients with thermal injury. x2 statistical analysis
demonstrated significant associations with sGPVI and the pro-
portion of patients developing sepsis and patient outcome
(P , .001), with overrepresentation of patients bearing high sGPVI
developing sepsis across all times (supplemental Table 5). Signif-
icant sGPVI associations with sepsis patient outcome at D7 and
D14 postinjury were observed when examining set times (P5 .023
and .043, respectively). Interestingly, sGPVI association with sepsis
Table 1. sGPVI correlations with clinical and biological parameters of
ICU patients
Variable 1 Variable 2 n r P
sGPVI Age 83 0.074 .50
Sex 83 20.011 .93
Stroke 83 0.18 .11
Aspirin before admission 83 20.16 .15
Diabetes 83 0.001 .99
SOFA score 83 0.22 .046
APACHEII score 83 0.45 <.0001
C-reactive protein 83 0.41 .0001
Fibrinogen 83 0.29 .009
PTT 83 20.13 .26
Platelet count 83 0.36 .0008
D-dimers 83 0.41 .0001
ISTH DIC score 83 0.28 .011
Leukocyte count 83 0.43 <.0001
IL-2 79 20.21 .06
TNFa 68 20.004 .98
IL-10 79 0.012 .92
sCD40L 79 20.19 .088
IL-17A 79 20.14 .22
IL-6 79 20.029 .8
IL-7 79 20.25 .024
IFNg 46 20.21 .17
Platelet-bound fibrinogen (MFI) 82 0.36 .0009
Platelet P-selectin (MFI) 82 0.14 .22
Spearman’s correlation coefficients, represented as r values, between sGPVI levels and
clinical/biological parameters measured from samples taken on day 1 (T1) on admission to
ICU. Significance observed when P , .05. Bold indicates significant correlation.
MFI, mean fluorescence intensity; PTT, partial thromboplastin time.
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at D7 and D14 was strengthened when corrected for platelet count
(supplemental Table 5).
Longitudinal statistical prediction models were used to evaluate
sGPVI as a predictive marker of sepsis (Figure 2F). The sGPVI
discriminatory value for predicting sepsis in patients with thermal
injury, represented as an area under the receiver operating
characteristic (AUROC) curve value, was determined using a linear
mixed-effects model of sGPVI and time and identified that D14
provided the strongest predictive value for sepsis (AUROC, 0.73)
and multiple-organ failure (AUROC, 0.77; supplemental Table 8).
Multivariate analysis of sGPVI with platelet count strengthened the
sepsis predictive value at D3, D7, and D14 (P 5 .75-.78;
supplemental Table 9).
Logistic regression was performed to assess sGPVI associations
with mortality in the patients with thermal injury with 15% or more
TBSA burns and compared with D-dimer levels. Significant
associations of sGPVI levels at D1 and 28-day mortality were
observed (P , .05; supplemental Table 6). After correcting for
platelet count, D1 sGPVI mortality association was not significant,
but it was at D14 and D21 (supplemental Table 7). Interestingly,
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D-dimer association with 28-day mortality was not significant (supple-
mental Table 7). D7, D14, and D28 samples postinjury gave the best
sGPVI discriminatory predictive values for predicting mortality at 1 year
(represented as AUROC, 0.68-0.75; supplemental Table 8). Mortality
predictive values of sGPVI were also improved when adjusted for
platelet count (supplemental Table 7). Multivariate analysis of sGPVI with
platelet count improved the predictive value at D3, D7, and D14 for
predicting mortality (P 5 .71-.83; supplemental Table 9). sGPVI and
ABSI values on D1 enhanced or maintained predictive power for sepsis
(AUROC, 0.80; compared to AUROC, 0.77 for ABSI alone) and
mortality (AUROC, 0.80; unchanged from ABSI alone). sGPVI and
APACHE(II) together demonstrated improved prediction of mortality
from D3 to D28 (supplemental Table 10). Together, these data suggest
sGPVI could be a useful addition to other clinical parameters for
predicting sepsis and mortality.
sGPVI is elevated in patients with IBD with active UC
We assessed plasma sGPVI levels in 42 patients with IBD to
compare sGPVI levels in patients with chronic inflammation. sGPVI
was elevated in patients with active UC compared with patients with
inactive UC and HCs, and was distributed more broadly, likely
because of disparate levels of inflammation in this cohort
(Figure 3A). Plasma sGPVI levels in active and inactive Crohn’s
disease were not significantly elevated above HC values, possibly
indicating a reduced inflammatory status compared with patients
with active UC. There was no significant correlation between sGPVI
and platelet count (supplemental Table 11) in these patient groups.
Iron deficiency anemia is commonly associated with IBD. We
investigated whether there was a link between platelet activation, IBD
inflammatory status observed, and iron deficiency. When stratifying
patients with IBD on the basis of hemoglobin levels, an indicator of
iron deficiency, patients with low hemoglobin (,120 g/L) showed
highly elevated sGPVI levels compared with patients with hemoglobin
levels above 120 g/L and HCs (Figure 3B). Hemoglobin levels
negatively correlated with plasma sGPVI levels (supplemental
Table 11). Furthermore, ferritin levels, another indicator of iron
deficiency, negatively correlated with sGPVI in patients with active
IBD with C-reactive protein levels greater than 5 mg/mL.
Exposure of platelets to fibrin, but not GPCR
stimulation, induces GPVI shedding
Engagement of GPVI by collagen, CRP, or convulxin leads
to ITAM-signaling dependent metalloproteolytic release of a
55-kDa sGPVI fragment, leaving a 10- to 15-kDa membrane-bound
remnant.23,24,26,27,43 To ascertain whether fibrin could induce GPVI
shedding, we first assessed the effect of thrombin or other GPCR
ligands onGPVI levels. GPVI sheddingwas calculated as a percentage
of GPVI detected in unstimulated samples compared with GPVI levels
after stimulation. Figure 4A shows that 1-hour treatment of washed
platelets with thrombin induced a loss of full-length GPVI that was
comparable to shedding achieved by collagen or CRP and similar loss
to the potent GPVI shedder, A23187 (Figure 4C). These treatments
induced the appearance of the 10- to 15-kDa remnant in ;50% of
donors. In contrast, treatment with adenosine 59-diphosphate (ADP),
the PAR-1 or PAR-4 peptide agonists, or thromboxane mimetic
U46619 did not induce loss of intact GPVI (Figure 4B-C).
As engagement of PAR-1 or PAR-4 via activating peptides did not
induce GPVI cleavage, and GPVI does not carry a recognized
Table 2. Correlations of sGPVI with D-dimers in patients with thermal
injury
Time
sGPVI Normalized sGPVI
n r P n r P
HC 12 0.03 .943 — — —
D1 49 0.17 .242 40 0.297 .062
D3 75 20.15 .190 64 20.315 .011*
D7 35 0.04 .808 30 0.127 .503
D14 44 0.46 .002** 40 0.643 <.001***
D21 42 0.32 .042 33 0.438 .011*
D28 35 0.39 .021* 29 0.540 .003**
M2 33 0.44 .011* 23 0.250 .250
M3 20 0.28 .239 11 0.041 .908
M6 18 0.35 .188 8 0.333 .428
M12 12 0.27 .387 7 0.714 .088
All times 341 0.349 <.001*** 286 0.155 .009**
Spearman’s correlation coefficients, represented as r values, between sGPVI levels and
normalized sGPVI corrected for platelet count and D-dimer levels in patients with thermal
injury at different points at injury. Bold indicates significant correlation.
*P , .05.
**P , .01.
***P , .005.
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thrombin-cleavage site, we considered whether GPVI shedding was
secondary to GPVI/fibrin engagement. Platelets were treated with
thrombin in the presence of fibrinogen to produce fibrin. This
treatment triggered loss of intact GPVI (Figure 5A) and was
comparable to A23187-induced shedding. Fibrinogen alone did not
induce GPVI shedding (Figure 5A), and shedding required fibrin
polymerization as inclusion of GPRP ablated GPVI proteolysis
(Figure 5A-B), demonstrating that fibrin polymers were more
effective than monomers at inducing shedding.
To assess whether fibrin-induced GPVI shedding required ITAM
signaling, platelet suspensions were pretreated with maximally
effective concentrations of Src and Syk inhibitors, dasatinib, and
PRT060318. GPVI shedding induced by thrombin-fibrinogen in
the presence of either inhibitor was not different to fibrin alone
(Figure 5), indicating that an active ITAM signaling pathway was
not crucial for fibrin-induced GPVI shedding. The role of multiple
metalloproteinases in fibrin-induced GPVI shedding was de-
termined by inclusion of GM6001, a broad metalloproteinase
inhibitor, or GI254023, an inhibitor of A Disintegrin and Metal-
loproteinase (ADAM) 10, to platelet suspensions, with both
having minimal effect on reducing fibrin-mediated shedding
(Figure 5B).
Discussion
The incidence, management, and knowledge of pathophysiological
processes relating to sepsis have improved during the last 20 years;
however, sepsis remains a significant public health problem across
the world, with more than 31 million cases presenting annually and
sepsis-related fatality occurring in 1 in 5 cases.44,45 Biomarkers with
high sensitivity and specificity that rapidly and accurately differen-
tiate sepsis from noninfectious conditions including systemic
inflammatory response syndrome are therefore in demand to help
implement the correct therapeutic regime. Diagnosis of sepsis is a
subjective clinical judgment focused on assessing the roots of
sepsis, using tools such as the SOFA or APACHE scoring
systems,46-48 with both systems including evaluation of patient
platelet count. Blood rheology and platelet function are pro-
gressively and severely altered in patients with severe sepsis.49,50
Evidence suggests a prominent role for inappropriate platelet
activation and aggregation during sepsis,51 and platelet indices
beyond platelet count are useful to evaluate illness severity and
prospectively identify critically ill patients.52,53 In this regard, sGPVI
represents an excellent candidate marker of pathological platelet
activation in the setting of sepsis, as it is a platelet/megakaryocyte-
specific membrane protein that is stable on circulating platelets but
-
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Figure 4. Stimulation of platelets with GPCR agonists do not induce GPVI shedding. (A) Western blot for GPVI after platelet stimulation by GPVI agonists, thrombin,
or A23187. Washed platelets (500 3 109/L) were stimulated with collagen (30 mg/mL), CRP (30 mg/mL), thrombin (1 U/mL), and calcium ionophore (A23187: 10 mM), a
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ANOVA with Tukey’s posttest was performed to compare shedding with unstimulated platelets. n 5 81 donors.
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released on ligand engagement of ITAM receptors, exposure to
FXa, or abnormal fluid shear rates.54 sGPVI levels are not elevated
as a consequence of ablated platelet production.55
We have investigated the utility of sGPVI as a marker of platelet
activation in these pathological settings and explored the value of
sGPVI to aid diagnosis and predict patient outcomes in conjunction
with standard clinical parameters, including platelet count and injury
severity scores. We have also investigated mechanisms that may
drive release of sGPVI in trauma/inflammation patients. Elevated
sGPVI levels were detected in the plasma of patients with thermal
injury and patients with IBD with active disease. Although there
were no significant sGPVI elevations in patients with ICU, we found
significant correlations with sGPVI levels and other biological
parameters including ISTH DIC score, C-reactive protein, and injury
severity scores (APACHEII, SOFA). sGPVI levels no longer
predicted mortality in ICU sepsis patients after correction for
disease severity.
sGPVI was not elevated during the acute thermal injury phase but
became significantly elevated with sepsis development. Dissemi-
nated intravascular coagulation is commonly observed in septic
patients. Platelets are activated and form fibrin-rich thrombi, leading
to further platelet activation. Fibrin accumulates during acute
inflammation and tissue injury and underlies sepsis pathology.4,5
D-dimers, a fibrin byproduct of coagulation and clot resolution
produced by the action of plasmin, are an indirect index of fibrin
formed in these patients. D-dimer levels correlated with sGPVI
levels in ICU patients and patients with thermal injury, even when
correcting for platelet count, suggesting a potential link between
sGPVI and fibrin in multiple patient cohorts. In support of this, sGPVI
levels significantly correlated with platelet-bound fibrin(ogen) in
samples from ICU patients, indicating both fibrin formation and
platelet activation. Synergy between D-dimer and sGPVI levels in
both ICU and thermal injury patient cohorts implies a role for fibrin in
GPVI shedding observed in these patients.
Spontaneous aggregation of platelets and hyperfibrinogenemia are
enhanced in the acute period (,48 hours) after thermal trauma.56
We found that sGPVI levels were significantly elevated in patients
with burn injuries at D14 postinjury. Low sGPVI levels were
observed at earlier points, suggesting that only a fraction of platelets
were activated by the injury and related collagen exposure, or that
low sGPVI levels reflected low platelet counts. When sGPVI levels
were adjusted for platelet count, there was significant elevation at
D3 postinjury in septic patients and sGPVI remained elevated at D7
and D14. As minimal collagen exposure is expected at these times,
an alternative mechanism for platelet activation and GPVI shedding
is likely.
We observed associations between sepsis and high sGPVI levels in
patients with thermal injury at all points when stratifying sGPVI levels
into low (#12.7 ng/mL), medium (.12.7 to#37.7 ng/mL), and high
(.37.7 ng/mL) levels. These associations were improved when
sGPVI levels were corrected for platelet count. Significant
associations with sGPVI and sepsis were observed at D7,
potentially correlating to sepsis onset. A longitudinal statistical
prediction of sGPVI levels in septic and nonseptic patients over time
indicated sGPVI having moderate value for predicting sepsis at early
points with a score of 0.68 at D7 and 0.73 at D14, which improved
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when correcting for platelet count (0.76 and 0.80, respectively). The
discriminatory power of sGPVI for predicting sepsis was also improved
after multivariate analysis, where sGPVI and platelet count were
combined (0.76 and 0.78, respectively). Furthermore, the discriminatory
power for sepsis prediction at D1 improvedwhen sGPVI was combined
with ABSI score, or at D3with APACHE(II). sGPVI discriminatory power
may further increase if used in combination with other strong sepsis
predictivemarkers such as cell-free DNA and immature granulocytes.37,38
This inflammatory trauma cohort presumably contained an abundance
of healthy people who were essentially well and unencumbered before
receiving their injury. Measurement of sGPVI on day 1 could potentially
enable clinicians to stratify patients based on sepsis risk and aid clinical
management of patients.
A longitudinal statistical prediction of sGPVI levels over time with all
patients with thermal injury gave a moderate value for mortality at
D14 and strengthened when corrected for platelet count or used in
combination with ABSI. In both cohorts, sGPVI associations with
mortality exceeded D-dimer associations with mortality. Together,
these data provide rationale for the combined analysis of sGPVI
levels in combination with other markers of sepsis onset and injury
severity scores and suggests sGPVI is a useful marker of platelet
activation and indicator for mortality risk and sepsis progression.
In the chronic IBD inflammatory cohort, sGPVI levels were elevated in
patients with active UC and correlated inversely with ferritin and
hemoglobin levels. Iron deficiency anemia is commonly associated with
IBD, with around 17% of patients with IBD having iron deficiency
anemia, increasing in prevalence to around 60% when studying
hospitalized patients.57,58 Although the molecular basis is unclear, there
are numerous links between iron deficiency and platelet activation.59
sGPVI levels may reflect platelet activation in iron-deficient patients with
IBD, which could also aid clinical management of these patients.
Fibrin was recently reported to activate platelets via GPVI, with the
interaction contributing to thrombus stabilization.11,12 Here we
demonstrate for the first time that fibrin-exposed platelets shed
GPVI to an extent comparable to GPVI ligands. GPVI shedding was
not a result of PAR engagement, as neither PAR-1- nor PAR-4-
activating peptides induced GPVI shedding. Treatment with ADP
and U46619 also failed to induce shedding, suggesting activation
of platelets via GPCRs is not sufficient to induce GPVI shedding.
Thrombin treatment variably stimulated GPVI shedding between
donors, consistent with other studies,23,26 which may depend on
sufficient fibrinogen storage and release from platelets and amount
of fibrin formed. GPVI lacks a recognized cleavage site for thrombin,
arguing against direct GPVI cleavage by the protease.
Fibrin generation is a potential consequence of disease for most
patient cohorts studied here, and as fibrin engages GPVI,11,12 we
assessed whether fibrin stimulation induced GPVI shedding.
Thrombin stimulation in the presence of fibrinogen consistently
induced GPVI shedding, independent of fibrinogen interaction
with integrin aIIbb3, as shedding occurred in the presence of
eptifibatide. ADAM10 plays a major role in GPVI shedding, with
ADAM17 contributing, at least in mice.60,61 Fibrin-induced sheddingwas
reduced but not blocked by GM6001 or by ADAM10-specific inhibitor
GI254023, suggesting roles for multiple sheddases. Unlike collagen-
induced shedding,26 fibrin-inducedGPVI shedding did not require active
ITAM signaling. Exposure to elevated shear or FXa induces shedding
that is also independent of platelet activation.62,63 Fibrin binds to multiple
proteins on the platelet surface; 1 or more of these interactions may
contribute to GPVI shedding, possibly by clustering and juxtaposing
GPVI to ADAM10 and/or other metalloproteinases. Further, soluble fibrin
can also reduce GPVI ligand-induced function in platelets, presumably
by blockade or steric hindrance of the ligand binding site, as the effect
was not blocked by GM6001.64
Monomeric fibrin, the predominant species in the presence of GPRP,
induced only minimal GPVI shedding, as determined by the inhibitory
effect of GPRP. This is consistent with fibrin-mediated activation of
GPVI in platelet suspensions requiring fibrin polymerization,11,12
although monomeric fibrin and D-dimer can activate GPVI when
immobilized.11,65 Targeting the conformational state of fibrin, or
blocking the fibrin-GPVI interaction,65 may permit modulation of fibrin-
mediated GPVI shedding and GPVI responsiveness.64
In conclusion, sGPVI and D-dimer levels fluctuate coincidentally in
injured patient cohorts where there is ongoing coagulopathy. We
have shown that sGPVI levels are predictive of patient outcomes
and enhance the predictive power of the APACHE and ABSI
clinical evaluation tools in a thermal injury cohort. The prognostic
value of measuring sGPVI should therefore be prospectively
evaluated in large cohorts of patients in whom sepsis is an
expected outcome. Our data support a role for fibrin-inducing GPVI
shedding, potentially explaining elevated sGPVI levels where there
is minimal exposure to collagen. Plasma sGPVI strongly associates
with onset of sepsis and with mortality, supporting the relevance of
sGPVI as a clinical platelet activation marker.
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